Amphastar Pharmaceuticals AMPH CN — Non-Current Assets
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NoncurrentAssets.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's cn — non-current assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's CN — non-current assets?
- Amphastar Pharmaceuticals (AMPH) reported CN — non-current assets of $108.56M in Q1 2026.
- How has Amphastar Pharmaceuticals's CN — non-current assets changed year-over-year?
- Amphastar Pharmaceuticals's CN — non-current assets decreased by 1.7% year-over-year, from $110.48M to $108.56M.
- What is the long-term trend for Amphastar Pharmaceuticals's CN — non-current assets?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's CN — non-current assets has grown at a 4.1% compound annual growth rate (CAGR), from $375.63M to $440.58M.
- What does CN — non-current assets mean?
- This metric measures the long-term assets held by the company within the specified segment that are not expected to be converted into cash within a single fiscal year. These assets typically include long-term investments, intangible assets, and other non-liquid holdings essential for regional operations. Monitoring this balance provides insight into the company's long-term capital commitment and infrastructure investment within this specific market.